Harsh Parmar, MD

Articles by Harsh Parmar, MD

Linvoseltamab Data and Clinical Perspectives in Relapsed/Refractory Multiple Myeloma

ByShambavi Richard, MD,Prashant Kapoor, MD,Mansi Shah, MD,Ridhi Gupta, MD,Cesar Rodriguez, MD,Harsh Parmar, MD,Gurbakhash Kaur, MD

July 29th 2026

Dr. Prashant Kapoor reviews the pivotal phase 1/2 LINKER-MM1 study evaluating linvoseltamab, a BCMA × CD3 bispecific antibody, in heavily pretreated patients with relapsed/refractory multiple myeloma (R/R MM).

Introduction to BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

ByShambavi Richard, MD,Prashant Kapoor, MD,Mansi Shah, MD,Ridhi Gupta, MD,Cesar Rodriguez, MD,Harsh Parmar, MD,Gurbakhash Kaur, MD

July 29th 2026

Dr. Shambavi Richard welcomes viewers to Cancer Network's FACE-OFF, introducing a debate-driven educational program focused on the evolving role of BCMA-targeted therapies in relapsed/refractory multiple myeloma (R/R MM).

Harsh Parmar, MD

Articles by Harsh Parmar, MD

Linvoseltamab Data and Clinical Perspectives in Relapsed/Refractory Multiple Myeloma

Introduction to BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

Latest Updated Articles

Trending on CancerNetwork

Ris-Rez Hits PFS End Point in Phase 3 Osteosarcoma Trial

Developing A Precision Approach to CAR T-Cell Toxicity Management

RP1's Long Road: A Timeline of RP1's Regulatory Journey in Advanced Melanoma

Implementing GU Takeaways From the 2026 ASCO Into Clinical Practice

AI-Based Pan-TEAD Inhibitor Wins FDA Fast Track Designation in Mesothelioma